Status:
COMPLETED
Can Resistance Enhance Selection of Treatment? (CREST)
Lead Sponsor:
Kirby Institute
Collaborating Sponsors:
Abbott
Boehringer Ingelheim
Conditions:
HIV Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To compare two commercially available platforms for assessment of HIV drug resistance to determine which provides superior virological results. We hypothesise that one test will be significantly supe...
Eligibility Criteria
Inclusion
- HIV infected patients taking combination antiretroviral therapy, with plasma HIV RNA\> 2000copies/mL, who were willing to change ARVs and who provided informed consent.
Exclusion
- Patients who were ARV naïve, who were experiencing an acute illness or judged to be unable to comply with the protocol requirements.
Key Trial Info
Start Date :
March 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2006
Estimated Enrollment :
338 Patients enrolled
Trial Details
Trial ID
NCT00262717
Start Date
March 1 2001
End Date
July 31 2006
Last Update
June 26 2025
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Interchange General Practice
Canberra, Australian Capital Territory, Australia
2
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, 2050
3
Sydney Sexual Health Clinic
Sydney, New South Wales, Australia, 2000
4
AIDS Research Initiative
Sydney, New South Wales, Australia, 2010